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Cyclooxygenase (COX)-1 and COX-2 are centrally important enzymes within the cardiovascular 
system with a range of diverse, sometimes opposing, functions. Through the production of 
thromboxane, COX in platelets is a pro-thrombotic enzyme. By contrast, through the production of 
prostacyclin, COX in endothelial cells is antithrombotic and in the kidney regulates renal function and 
blood pressure. Drug inhibition of COX within the cardiovascular system is important for both 
therapeutic intervention with low dose aspirin and for the manifestation of side effects caused by 
nonsteroidal anti-inflammatory drugs. This review focuses on the role that COX enzymes and drugs 
that act on COX pathways have within the cardiovascular system and provides an in-depth resource 
covering COX biology and pharmacology. The review goes on to consider the role of COX in both 
discrete cardiovascular locations and in associated organs that contribute to cardiovascular health. 
We discuss the importance of, and strategies to manipulate, the thromboxane: prostacyclin balance. 
Finally within this review the authors discuss testable COX-2-hypotheses intended to stimulate 
debate and facilitate future research and therapeutic opportunities within the field.  
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Cyclooxygenase (COX), also known as prostaglandin (PG)H synthase, is the first enzyme in the 
conversion of fatty acid substrates, most notably arachidonic acid, to PGH2. PGH2 is then further 
metabolized by downstream synthase enzymes to a range of prostanoids. COX can also use other 
fatty acid substrates including eicosapentaenoic acid (EPA) and dihomo-γ-linolenic acid resulting in 
PGH3 and PGH1, and associated prostanoid products, respectively; in prostanoid nomenclature, the 
subscript number (1 to 3) denotes the total number of double bonds in the alkyl substituents. The 
rate-limiting step in prostanoid formation from COX is availability of substrate. In resting cells 
arachidonic acid is highly restricted to plasma phospholipids and generally only released when cells 
are stimulated following activation of calcium dependent isoforms of phospholipase A2 (Flower & 
Blackwell, 1976; Kirkby, et al., 2015; Mitchell & Kirkby, 2019; Mitchell, et al., 2018). In some systems 
arachidonic acid can also be liberated from phosphatidylinositol by the phospholipase C pathway (de 
Nucci, Gryglewski, Warner, & Vane, 1988). 
  
COX is present in two isoforms, COX-1 and COX-2, derived from different genes and sharing ≈60% 
homology at the protein level (Kang, Mbonye, DeLong, Wada, & Smith, 2007). A third isoform (COX-
3), which is a spliced variant of COX-1 (Chandrasekharan, et al., 2002), has been described but 
because this variant retains intron-1, translation results in a frame shift producing a protein devoid 
of ‘COX’ activity in rats (Snipes, Kis, Shelness, Hewett, & Busija, 2005) and mice (Kis, et al., 2006) and 
with no predicted enzymatic activity in humans (Kis, Snipes, & Busija, 2005). For all intents and 
purposes, therefore, there are just two functional COX enzymes, COX-1 and COX-2. 
 
COX-1 has the traditional features of a house keeping gene (Azizkhan, Jensen, Pierce, & Wade, 1993) 
in that it lacks a canonical TATA or CAAT box and is GC-rich (Kang, et al., 2007). As such COX-1 is 
constitutively expressed in most cells to some degree and highly expressed in some tissues, including 
platelets and blood vessels. Whilst COX-1 is constitutively expressed its levels can be up regulated in 
endothelial cells by growth factors (Bryant, Appleton, & Mitchell, 1998) and physiological stimuli such 
as shear stress (Okahara, Sun, & Kambayashi, 1998).  
 
COX-2 on the other hand has the characteristics of an immediate early response gene with multiple 
cis-elements in the 5'-flanking region that regulate gene expression via transcription factors such as 
NFAT, CREB and NFκB (Kang, et al., 2007). As a result, COX-2 is rapidly induced at sites of inflammation 
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(Vane, et al., 1994) and in cancer (Hashemi Goradel, Najafi, Salehi, Farhood, & Mortezaee, 2019). 
Importantly, COX-2 is also constitutively expressed in the absence of inflammation (Mitchell & Kirkby, 
2019) in select regions such the brain, gut, thymus, lung and the inner medulla region of the kidney 
(Harris, et al., 1994; Kirkby, et al., 2016; Kirkby, et al., 2013; Mitchell, et al., 2018; Zidar, et al., 2009).  
 
Prostanoids are a group of highly potent lipid mediators with diverse effects, dictated by the presence 
of affiliated prostanoid receptors. Prostanoid receptors are classical G-protein-coupled receptors 
utilizing either cAMP or phosphatidylinositol signaling pathways (Alexander, et al., 2019) to regulate 
homeostasis and inflammation across all organ systems within the body.  
 
The COX pathway has been exploited therapeutically, although without doubt the full potential of 
COX and prostanoids in the treatment of human disease remains to be realised. In this regard, drug 
formulations of prostanoids derived from the COX pathway including prostacyclin (PGI2), PGE2, PGE1 
and PGF2α are used in a range of indications. For example, drug formulations of PGI2 (and related 
molecules) are used to treat pulmonary arterial hypertension and peripheral vascular disease. PGE2 
and PGE1 are used in labor, in babies with heart defects to control closing of the patent ductus 
arteriosus and as combination therapies with NSAIDs to prevent gastric ulcers, while synthetic forms 
of PGF2α are used to reduce intraocular pressure in the treatment of glaucoma. However, on a global 
and population level, the most important drug opportunity presented by the COX pathway is in 
compounds that block enzyme activity and subsequent prostanoid production. Nonsteroidal anti-
inflammatory drugs (NSAIDs), which include celecoxib, ibuprofen and naproxen, used in the 
treatment of pain and fever and aspirin (in low dose) used for the secondary prevention of heart 
attacks and strokes, all work by blocking COX. They represent some of the world’s most widely used 
prescription and over the counter medications. Shortly after COX-2 was discovered, early 
pharmacological studies identified key differences in the potency of NSAIDs between COX-1 and COX-
2 (Meade, Smith, & DeWitt, 1993; Mitchell, Akarasereenont, Thiemermann, Flower, & Vane, 1993; 
Warner, et al., 1999), these were later explained by structural differences in the active sites of the 
enzymes (Garavito, Malkowski, & DeWitt, 2002; Y. S. Khan, Gutierrez-de-Teran, & Aqvist, 2018). Since 
COX-2 is the therapeutic target of NSAIDs, selective COX-2 inhibitors were introduced to the market 
in the early 2000s to avoid the notorious gastrointestinal effects associated with traditional older 
style medications, which block both isoforms. COX-2 selective NSAIDs are comparable with 
traditional non-selective drugs for treating pain and inflammation with reduced gastrointestinal side 
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effects (Coxib, et al., 2013). However, now the major concern across all forms of NSAID therapy are 
the cardiovascular side effects associated with these drugs, which were only realised in the post 
2000s era. 
 
This review focuses on the role that COX enzymes and drugs that act on COX pathways have within 
the cardiovascular system. Drug inhibition of COX within the cardiovascular system is important for 
both therapeutic intervention and for the manifestation of side effects. This review considers the 
role of COX in both discrete cardiovascular locations and in associated organs that contribute to 
cardiovascular health. Finally within this review the authors discuss testable COX-2 hypotheses 
intended to stimulate debate and facilitate future research and therapeutic opportunities within the 
field.  
 
2. Cyclooxygenase expression and activity within the cardiovascular system  
As discussed above, COX-1 is a typical house-keeping gene that is expressed throughout the 
cardiovascular system with particularly high abundance in blood vessels and platelets. Within healthy 
blood vessels COX-1 is mainly located within the endothelial layer where it couples with prostacyclin 
synthase (PGIS) to produce mainly PGI2. In platelets COX couples with thromboxane (TXA2) synthase 
to produce mainly TXA2. While COX-2 is expressed in areas of vascular inflammation and disease it is 
only sparsely expressed in the majority of blood vessels and essentially absent in platelets. Studies 
from knockout mice confirm that COX-1 is the predominate driver of ‘gross’ PGI2 production. 
However, as discussed below, constitutive endothelial COX-2 does have cardio-protective effects, 
although the anatomical locations and mechanistic paradigm of endothelial COX-2 remain to be 
determined. 
 
3. The prostacyclin thromboxane balance 
PGI2 inhibits platelet activation and is thereby an anti-thrombotic mediator. PGI2 also inhibits lipid 
accumulation (Hajjar, et al., 1982) and vascular smooth muscle cell remodeling in humans in vivo 
(Sinzinger, et al., 1987) and in isolated vascular smooth muscle cells in vitro (Akopov, et al., 1988).  In 
direct contrast, TXA2 stimulates platelet activation (Crescente, Menke, Chan, Armstrong, & Warner, 
2019), increases cholesterol accumulation (Baldenkov, Akopov, Ryong, & Orekhov, 1988) and 
vascular smooth muscle cell proliferation (Akopov, et al., 1988). In this way, levels of PGI2 and TXA2 
operate within a tight margin of pro- and anti-thrombotic tone to keep blood flowing under 
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physiological conditions and allowing rapid platelet aggregation when needed for haemostasis 
(Knowles & Warner, 2019). Within limits, therefore, a healthy, protected cardiovascular system is 
one where PGI2 activity ‘outweighs’ TXA2 activity. Therapeutically the PGI2:TXA2 balance can be 
manipulated towards an antithrombotic tone by (i) reducing TXA2, (ii) boosting PGI2 or (iii) reducing 




Figure 1: The prostacyclin thromboxane balance and strategies for therapeutic manipulation. AA, 
arachidonic acid; EPA, eicosapentaenoic acid; COX, cyclooxygenase; PGIS, prostacyclin synthase; 
TXAS, thromboxane synthase; IP, I-prostanoid receptor; TP, T-prostanoid receptor; PPAR, peroxisome 
proliferator-activated receptor; HDL, high density lipoprotein; apoAI, apolipoprotein A-I. 
3.1. Reducing thromboxane 
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Inhibiting platelet COX-1 with low dose aspirin (70-120mg daily) can selectively reduce TXA2 and as 
aspirin is cheap and effective, this approach is used worldwide for secondary protection against 
arteriothrombotic events. The selectivity of aspirin against platelet COX-1 and consequently TXA2 
production is explained by its unique pharmacology, which separates it from other NSAIDs. Firstly, it 
is the only drug in the class that works irreversibly, and secondly it has a short half-life in the body. 
The irreversible mechanism of action of aspirin means that after tissues are exposed to it prostanoid 
production can only resume through the synthesis of new enzyme. As platelets have no nucleus they 
cannot generate new protein and remain inhibited for their lifetime. Conversely, because aspirin 
rapidly disappears from the circulation, its effects can be overcome between doses by regeneration 
of the enzyme in nucleated cells such as vascular endothelial cells and so the production of other 
prostanoids, notably PGI2, can be largely maintained (Heavey, Barrow, Hickling, & Ritter, 1985). 
Additional selectivity arises through the exposure of circulating platelets to higher levels of aspirin in 
the portal circulation, prior to first-pass hepatic metabolism, than in the systemic circulation meaning 
that the majority of the endothelium is somewhat protected from its effects. Together these 
processes mean that the cumulative effects of low dose aspirin therapy are to reduce platelet TXA2 
production by more than 95% while endothelial PGI2 production is partially preserved. The 
pharmacology of TXA2 and mechanistic explanations of how aspirin works in platelets is reviewed in 
detail by Crescente and colleagues (Crescente, et al., 2019). 
 
3.2. Boosting PGI2 
Boosting PGI2 at the effector site can be achieved in three functional ways; (i) increasing 
synthesis/release, (ii) stabilizing PGI2 and increasing its half-life and (iii) supplementing endogenous 
PGI2 with PGI2-drugs.  
 
3.2.1. Synthesis 
PGI2 release is regulated by the concerted actions of COX and PGIS. Reduced PGIS expression is seen 
in the lungs of patients with pulmonary arterial hypertension (Tuder, et al., 1999) and in the 
resistance arteries of patients with type 2 diabetes (Safiah Mokhtar, et al., 2013) whilst mutations in 
PGIS are linked to hypertension (Nakayama, et al., 2002), cerebral infarction (Nakayama, et al., 2000) 
and myocardial infarction (Nakayama, 2010). In line with this, increasing PGIS expression through 
gene therapy is an emerging therapeutic possibility, currently at the preclinical stage, with target 
indications including peripheral vascular disease (Shimamura, Nakagami, Taniyama, & Morishita, 
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2014), vein grafts (Newby & Baker, 1999), pulmonary hypertension (Nagaya, et al., 2000) and stroke 
(Lin, et al., 2002).  
 
An additional way in which PGI2 release can be increased is by selectively blocking PGE2 synthesis 
through the use of microsomal PGE synthase (mPGES)-1 inhibitors. PGE2 synthesis occurs by the 
concerted actions of COX and PGES or (under some conditions) non-enzymatically. There are 3 
isoforms of PGES, mPGES-1, mPGES-2 and cytosolic PGES. mPGES-1 is often co-expressed with COX-
2 and is an established therapeutic target for inhibitor drugs to treat inflammation and pain 
(Bergqvist, Morgenstern, & Jakobsson, 2019). Work from our group and others show that loss of 
mPGES-1 increases plasma PGI2 in mice in vivo (Kirkby, et al., 2019) or tissue PGI2 in human vessels 
(Ozen, et al., 2017). These observations are in line with reports showing that loss of mPGES-1 in mice 
can be cardio-protective since it slows atherosclerosis (Wang, et al., 2006), inhibits aortic aneurysm 
in hyperlipidemic mice (M. Wang, et al., 2008), and smooth muscle remodeling following vascular 
injury (Wang, et al., 2011). The relative contributions of increased PGI2 versus reduced PGE2 in the 
cardio protective effects of blocking of mPGES-1 remain to be established. 
 
3.2.2. Half-life 
PGI2 is unstable in aqueous solution at physiologic pH and temperature. This has given rise to the 
idea that PGI2 is a locally acting anti-thrombotic hormone (Christ-Hazelhof & Nugteren, 1981). 
However, PGI2 is stabilized by binding to serum proteins such that in blood or plasma PGI2 has a half-
life estimated to be between 3 to 15 minutes (Dusting, Moncada, & Vane, 1978; Pifer, Cagen, & 
Chesney, 1981) which, if applicable in vivo would suggest that PGI2 circulates (Moncada, Korbut, 
Bunting, & Vane, 1978). The ability of plasma to stabilize PGI2 is reduced in patients with 
cardiovascular disease including thrombotic thrombocytopenic purpura (Wu, Hall, Rossi, & Papp, 
1985), stroke (Stein, Papp, Weiner, & Wu, 1985), myocardial infarction (Sinzinger, Fitscha, & Tiso, 
1990) and unstable angina (Aoyama, Yui, Morishita, & Kawai, 1990). In addition to albumin, 
components of HDL, including apolipoprotein A-I have been identified as ‘stabilizing factors’ for PGI2 
(Yui, et al., 1988) leading to the idea that reduced HDL levels may contribute to cardiovascular risk 
due to reduced circulating levels of biologically active PGI2 (Pirich, Efthimiou, O'Grady, & Sinzinger, 
1997). Whilst the therapeutic utility of drugs designed to stabilize endogenous PGI2 remains to be 
determined, such drugs may be an attractive option particularly for those patients where changes in 
plasma constituents result in a reduced ability to stabilize PGI2. 
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3.2.3. PGI2 drugs 
In addition to boosting endogenous PGI2, the PGI2:TXA2 balance can be manipulated by supplying PGI2 
as a drug. PGI2 drugs are based on synthetic agonists of PGI2 receptor pathways. Much of the 
functional effects of PGI2 are mediated through activation of the cell surface prostacyclin (IP) 
receptor linked to activation of adenylate cyclase and increases in the second messenger cAMP. IP 
receptor pharmacology and signal transduction is reviewed in detail by Midgett and colleges 
(Midgett, Stitham, Martin, & Hwa, 2011). It should also be noted that when produced in excess of IP 
receptor capacity, PGI2 may also crosses over to other prostanoid receptors leading to 
vasoconstriction in some vessels (Luo, Liu, & Zhou, 2016).  
 
PGI2 can also activate the cytosolic nuclear receptor PPARβ. PPARβ signalling includes the classical 
PPAR-RXR pathway to regulate target gene induction and trans-repression of the transcription factor 
BCL-6 (Lee, et al., 2003) and/or protein kinase PKCα (Ali, Armstrong, et al., 2009; Ali, Hall, Desvergne, 
Warner, & Mitchell, 2009; Mitchell, et al., 2014). The pharmacological relationship between PGI2 
drugs in their interaction with IP versus PPARs is reviewed elsewhere (Belvisi & Mitchell, 2009; 
Bishop-Bailey, 2015; Mitchell, et al., 2014; Mitchell & Kirkby, 2019). PGI2 drugs include, injectable 
treprostinil, iloprost, beraprost and newer orally active selexipag (Mitchell, et al., 2014). They are 
perhaps surprisingly not used as anti-thrombotic medications but rather for the treatment of 
particular vascular diseases as mentioned above (Mitchell, et al., 2014). This is primarily because PGI2 
drugs are restricted by their side effects, which means their use is limited to conditions with finite 
therapeutic options. 
 
3.2.4. 2-series versus 3-series prostanoids: the arachidonic acid-EPA balance 
Finally, the PGI2:TXA2 balance can be indirectly manipulated by changing the ratio of COX substrate 
from omega-6 arachidonic acid to omega-3 EPA and docosahexanoic acid (DHA), resulting in the 
reduction of 2-series and increase of 3-series prostanoids. Arachidonic acid derived from meat, 
poultry, nuts and seeds, is a principle component of cell membranes (Tallima & El Ridi, 2018) and 
preferentially utilized by COX over other fatty acid substrates to produce PGH2. As such the common 
forms of ‘prostacyclin’ and ‘thromboxane’ within the body are derived from COX metabolism of 
arachidonic acid resulting in 2 double bonds in the alkyl substituents and as such are symbolised as 
PGI2 and TXA2 respectively.  Fish oils contain omega-3 DHA and EPA, which can replace omega-6 
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arachidonic acid in cell membranes, increasing the ratio of omega-3:omega-6 fatty acids, which is 
associated with cardiovascular protection (Calder, 2017; Innes & Calder, 2018). This can be modelled 
in rats fed fish oil supplemented feed for anything from 1 week to 8 months (Chen, et al., 2000; 
McIntosh, McLennan, Lawson, Bulman, & Charnock, 1985) and in mice for 2 weeks (Gong, et al., 
2015). In an endotoxemia rat model, continuous enteric feeding with an EPA diet showed its 
assimilation into tissues was relatively rapid with maximal incorporation seen after 3 days (Palombo, 
et al., 1996). EPA may be more important than DHA in omega-3 fatty acid preparations for 
cardiovascular health since the EPA:arachidonic acid ratio is more predictive than the 
DHA:arachidonic acid ratio with regard to cardiovascular events (Nelson & Raskin, 2019). Similarly, in 
clinical formulations DHA but not EPA increases atherogenic LDL levels (Chang, et al., 2018).  
 
Clinical formulations of omega-3 oils include LovazaTM, which is a combination formulation of ethyl 
esters of EPA (ethyl EPA also known as icosapent ethyl) and DHA and VascepaTM which is a single 
formulation of ethyl EPA. LovazaTM and VascepaTM are both used to treat hypertriglyceridemia as an 
adjunct or substitute to statin therapy although discussion continues regarding the use of ethyl EPA 
over other regimes such as fibrates (Doggrell, 2019). Most recently, data from the REDUCE-IT trial, 
which used a higher a dose (4g/day) than other trials of VascepaTM, showed that the single ethyl EPA 
therapy reduced cardiovascular events independently of triglyceride levels (Bhatt, et al., 2019) 
providing renewed interest in the pleiotropic mechanisms by which fish oils protect the 
cardiovascular system (Calder, 2017; Nelson & Raskin, 2019). These potential pleiotropic mechanisms 
include membrane stabilisation and reduced oxidant stress. Additionally, of relevance to this review, 
EPA competes with arachidonic acid as a substrate for COX, with greater selectivity towards COX-1 
than COX-2 giving rise to PGH3 derived prostanoids including PGI3 and TXA3 (Back, 2017).  
 
Synthetic forms of PGI3 are available commercially making its pharmacology easily accessible and 
where tested PGI3 and PGI2 elicit equal inhibitory effects on human platelet aggregation (Kobzar, 
Mardla, Jarving, & Samel, 2001; Wada, et al., 2007). By contrast, it is commonly reported that TXA3 
is less potent an activator of platelet aggregation than TXA2 (Back, 2017). However, TXA3 is not 
commercially available which has made direct pharmacological comparisons with TXA2 difficult. 
Nevertheless, the fact that EPA shifts the balance of pro-thrombotic TXA2 towards anti-thrombotic 
PGI3 is commonly reported and explains, if only in part, the cardio protective effects of fish oil and 
clinical formulations of EPA.     
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4. Effects of NSAIDs in the cardiovascular system 
As discussed above, low dose aspirin is a popular and important cardio-protective drug because it 
selectively blocks COX-1 in platelets and reduces the TXA2:PGI2 balance. However, other drugs in the 
NSAIDs class are associated with increased risk of cardiovascular side effects including hypertension 
(White, 2007), stroke (Fanelli, Ghisi, Aprile, & Lapi, 2017), heart attacks (McGettigan & Henry, 2011) 
and heart failure (Ungprasert, Srivali, & Kittanamongkolchai, 2015).  
 
Cardiovascular side effects were initially thought to be limited to COX-2 selective drugs such as 
rofecoxib and celecoxib introduced 20 years ago. However, after almost 20 years of clinical evidence 
(McGettigan & Henry, 2011; Pirlamarla & Bond, 2016) addressing cardiovascular side effects in NSAID 
users we now know that all NSAIDs are associated with risk. This is not only evidenced by systematic 
review and meta-analysis but by two large clinical cardiovascular outcome studies, SCOT (T. M. 
MacDonald, et al., 2016) and PRECISION (Nissen, et al., 2016), that showed that traditional NSAIDs, 
including ibuprofen and naproxen, carry at least as great a cardiovascular risk as the COX-2 selective 
drug celecoxib, with ibuprofen emerging as significantly more toxic to the kidney at therapeutic doses 
(Nissen, et al., 2016). Importantly, the increased risk of cardiovascular events whilst on NSAIDs, 
including ibuprofen, can be seen after only 1-2 weeks of regular use (Bally, et al., 2017).  
 
The context and scale of NSAID associated cardiovascular side effects in the population (Mitchell & 
Kirkby, 2019), their unintended impact on opioid use (Stokes, Berry, Hempstead, Lundberg, & Neogi, 
2019) and the missed opportunity to prevent cancer (Mitchell & Kirkby, 2019) are discussed 
elsewhere and together highlight the need for continued research in the area. However, the specific 
downstream mechanisms by which NSAIDs cause cardiovascular side effects are incompletely 
understood but it is clear that blocking COX-2 is the fulcrum and that incidental blockade of COX-1 
by traditional NSAIDs does not mitigate the risk of cardiovascular side effects. Explaining this is 
difficult and needs to take account of (i) the specific role that COX-1 versus COX-2 plays in PGI2 
formation (discussed in detail below), (ii) the PGI2:TXA2 balance (discussed above) and (iii) the 
potential for PGI2 to act as a constrictor in some vascular beds in some settings. This last point is 
covered in detail elsewhere (S. Khan, Andrews, & Chin-Dusting, 2019; Luo, et al., 2016) and discussed 
briefly below. Finally, it should also be noted that blocking COX enzymes can result in shunting of the 
substrate arachidonic acid to other enzyme pathways, such as 5-lipoxygenase (5-LOX). 5-LOX is 
	 14	
expressed in leukocytes and utilizes arachidonic acid to produce leukotriene A4 (LTA4) (Dennis & 
Norris, 2015; Martel-Pelletier, Lajeunesse, Reboul, & Pelletier, 2003). While vascular cells do not 
contain 5-LOX, endothelial cells can metabolise LTA4 to LTC4, LTB4, LTD4, and LTE4. LTs are implicated 
in the pathological processes associated with atherosclerosis and inflammation(de Gaetano, Donati, 
& Cerletti, 2003). Thus, blocking COX with NSAIDs could result in the shunting of arachidonic towards 
LTC4 in immune cells and on to other LTs in endothelial cells, potentially contributing to the 
cardiovascular side effects seen with NSAIDs. While the importance of this pathway in the 
cardiovascular effects caused by NSAIDs remains unclear, the use of combined COX/LOX inhibitor 
drugs may offer therapeutic solutions to some of the side effects caused by blocking COX-2 (Martel-
Pelletier, et al., 2003). 
 
5. Mechanisms by which cyclooxygenase protects the cardiovascular system 
5.1. COX-1 
As discussed above, COX-1 is expressed throughout the vasculature (Zidar, et al., 2009) where it 
produces largely PGI2. However, a protective vasodilator or anti-thrombotic role of endogenous PGI2 
has been difficult to demonstrate in humans in vivo. This is because global peripheral endothelial 
dependent vasodilation and thrombotic tone are difficult to faithfully measure in humans and 
because COX-1 drives prostacyclin and the counter, vasoconstrictor, pro-thrombotic hormone, TXA2. 
In terms of vascular responses, a vasodilator function of endogenous PGI2 has been inferred in studies 
using flow-mediated vasodilation measured at the brachial artery after acute dosing with NSAIDs. 
For example, acutely inhibiting COX with traditional NSAIDs that block COX-1 as well as COX-2 
including aspirin, indomethacin, diclofenac, naproxen or piroxicam reduced flow-mediated dilatation 
(reactive hyperaemia) in humans, particularly at the peak of the response (Carlsson, Sollevi, & 
Wennmalm, 1987; Carlsson & Wennmalm, 1983; Engelke, Halliwill, Proctor, Dietz, & Joyner, 1996; 
Kilbom & Wennmalm, 1976; Wilson & Kapoor, 1993). However, locally infused aspirin did not inhibit 
forearm blood flow stimulated by bradykinin in healthy volunteers (Benjamin, et al., 1989). By 
contrast, in healthy volunteers, aspirin (Noon, Walker, Hand, & Webb, 1998) or diclofenac (Hojs, 
Strucl, & Cankar, 2009) reduced acetylcholine induced micro vascular vasodilatation in the skin. 
However, protocols that used longer duration of dosing and/or selective COX-2 inhibitors have 
produced mixed results. Flow mediated dilation in osteoarthritis patients was not affecting by 
naproxen or diclofenac after 7 days of dosing (Solmaz, et al., 2012). In addition, neither naproxen nor 




volunteers after 7 days of dosing (Verma, Raj, Shewchuk, Mather, & Anderson, 2001). Furthermore, 
in both hypertensive subjects (Widlansky, et al., 2003) and subjects with peripheral arterial disease 
(Florez, et al., 2009) celecoxib actually increased flow-mediated dilatation after acute (3 hours) or 
longer term (7 days) of dosing.    
 
In terms of thrombosis, there is no clinical evidence that selectively blocking COX-1 mediated-PGI2 
release increases thrombosis. This is likely because there are no drugs currently in use that selectively 
target endothelial COX-1 and so there are no pharmacological means of selectively blocking COX-1 
mediated PGI2 release. In animal models, selective COX-1 inhibitors or global COX-1 knockout where 
both PGI2 and TXA2 are blocked the overriding phenotype is dictated by loss of TXA2 (rather than loss 
of PGI2) resulting in reduced thrombosis. However, recent work from our group using endothelial 
cell-specific COX-1 knockout mice has demonstrated that selective loss of prostacyclin increases 
thrombosis, thereby confirming that systemic COX-1 derived PGI2 formation provides an endogenous 
homeostatic brake on platelet activation (Mitchell, et al., 2019). The clinical translation of this work 
is likely relevant in ageing where TXA2 levels increase with age (Iyer & Dayal, 2019) whilst circulating 
levels of the PGI2 (measured as the breakdown product as 6-keto PGF1α) decreases from 400 pg/ml 
in new born infants, to 230 pg/ml in infants, 150 pg/ml in adolescents, and 85 pg/ml in adults (Kaapa, 
Viinikka, & Ylikorkala, 1982). Age related loss of plasma levels of PGI2 is not due to reduced COX-1 or 
PGIS expression but is suggested to be caused by accelerated degradation (Qian, Luo, & Chi, 2012). 
 
5.2. COX-2 
A cardio-protective role of COX-2 is easily demonstrated as discussed above in numerous clinical 
studies, systematic reviews and meta-analysis. Moreover, inhibition or genetic deletion of COX-2 in 
mice causes increased thrombosis (Mitchell, et al., 2019; Yu, et al., 2012), decreased bleeding time 
(Cheng, et al., 2006), reduced renal function (Ahmetaj-Shala, et al., 2015; Kirkby, et al., 2019; M. Z. 
Zhang, et al., 2015), increased blood pressure (Ahmetaj-Shala, et al., 2015; Cheng, et al., 2006) and 
(in some models) accelerated atherosclerosis (Kirkby, et al., 2014; Tang, et al., 2014). However, COX-
2 is not normally expressed within the systemic vasculature (Kirkby, et al., 2012) and is not linked to 
vascular PGI2 production (Kirkby, et al., 2012; Kirkby, et al., 2013; Li, et al., 2016; Liu, et al., 2012) or 
plasma levels of PGI2 (Kirkby, et al., 2014; Kirkby, et al., 2013). Whereas, COX-2 is constitutively 
expressed in select structures and regions of the body. These include (i) kidney, (ii) some vessels, (iii) 
gut, (iv) thymus and (v) brain (Mitchell & Kirkby, 2019). The concept of organ crosstalk in 
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cardiovascular disease is now well established and whilst we do not yet fully understand the 
mechanisms by which COX-2 protects the cardiovascular system and thereby how inhibition of COX-
2 by NSAIDs causes cardiovascular side effects, hypothesis can, and have been, generated to explain 
how COX-2 in remote regions could function to maintain cardiovascular health. The role that COX-2, 
identified in tissues outside the traditional cardiovascular system, may play in cardiovascular health 
is discussed below and summarised in Table 1 and Figure 2. 
 
5.2.1. Kidney 
Inhibition of COX-2 in the kidney as a contributory mechanism to explain the cardiovascular risk 
associated with NSAIDs is not new. The well-established role of the kidney in controlling blood 
pressure means that renal physiology and pharmacology is central to most common cardiovascular 
diseases. COX-2 is expressed constitutively in the kidney, including within the medulla interstitial 
fibroblasts, tubular epithelial cells and renal endothelial cells (Harris, 2006; Komhoff, Grone, Klein, 
Seyberth, & Nusing, 1997; Radi & Khan, 2019) where its expression is driven by the transcription 
factor, NFAT (Kirkby, et al., 2016). Constitutive COX-2 in the kidney regulates fundamental aspects of 
renal homeostasis including renal hemodynamics, body water and sodium balance, renin release and 
angiotensin II formation. Inhibition of renal COX-2 with NSAIDs therefore increases blood pressure 
(Harris, 2006). Of note, in a systematic analysis of regional blood flow, we found that of all of the 
regions where COX-2 is expressed constitutively, blood flow is only demonstrably reduced, by acute 
COX-2 inhibition, in the kidney (Mitchell, et al., 2018). 
 
In addition to established renal pathways we have identified >1000 genes altered in the renal medulla 
of germ line COX-2 knockout mice. Within this large set were genes encoding proteins important for 
multiple cardiovascular pathways including systemic blood pressure regulation, blood vessel size 
regulation, angiotensin and endothelin-1 biosynthesis, and nitric oxide (NO) and methylarginine 
biosynthesis (Ahmetaj-Shala, et al., 2015). Methylarginines, including asymmetric dimethylarginine 
(ADMA), are endogenous inhibitors of endothelial NO synthase (eNOS) and have previously been 
suggested as potential contributors to the cardiovascular side effects caused by NSAIDs (Fosslien, 
2005). There is strong precedence for this suggestion since ADMA is increased in both early and end 
stage kidney disease (Sitar, 2016) and is a biomarker of cardiovascular disease (Schlesinger, Sonntag, 
Lieb, & Maas, 2016). Moreover, the COX inhibitor indomethacin reduces DDAH (which metabolises 
ADMA) expression and increases ADMA levels in gastric tissue in rats (Shahin, Abdelkader, & Safar, 
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2018; L. Wang, et al., 2008) while the PGI2 drug iloprost reduces plasma levels of ADMA in patients 
with peripheral vascular disease (Blardi, et al., 2006) or Burger’s Disease (Senol & Senol, 2017). In 
support of the suggestion by Fosslien (Fosslien, 2005), we found that PRMT1 (which synthesizes 
ADMA) was increased whilst genes responsible for ADMA removal (DDAH1 and AGXT2) were reduced 
in kidneys from COX-2 knockout mice. In line with this, we found that ADMA levels were increased in 
the plasma of COX-2 knockout mice and in healthy volunteers taking naproxen or celecoxib. Further 
recent work from our group has validated these observations showing that pharmacological 
inhibition of COX-2 in mice using parecoxib increases plasma ADMA and that this is associated with 
PGI2 but not PGE2 signaling (Kirkby, et al., 2019).  
 
In our studies we used models of COX-2 deletion or pharmacological inhibition in mice or in human 
subjects where blood pressure was increased and/or renal function was reduced. This seems to be 
an important factor in the COX-2/ADMA axis since ADMA was only increased in arthritic rats by 
diclofenac (which increased blood pressure) but not celecoxib (which in their study did not increase 
blood pressure) (Verhoeven, et al., 2017) and because in models where COX-2 was inhibited or 
knocked out post-natally and which displayed normal blood pressure and/or renal function, ADMA 
was not increased (Ricciotti, et al., 2018). Taken together these studies further support a role for 
renal COX-2 in any associated elevation in plasma ADMA caused by NSAIDs; this is entirely in line with 
the recognized role that kidney COX-2 plays in cardiovascular protection (Walker & Biasucci, 2018). 
 
Finally, we found a functional indication for increased ADMA in COX-2 knockout mice since eNOS 
responses in aorta were reduced (Ahmetaj-Shala, et al., 2015) despite normal levels of local PGI2 
production. Others have also found that aortas from COX-2 knockout mice have reduced eNOS 
responses but in those studies this was attributed to reduced eNOS expression (Yu, et al., 2012). 
eNOS is present in the endothelium of all blood vessels where its basal activity protects the 
cardiovascular system from atherosclerosis, thrombosis and hypertension. NO and PGI2 have 
common protective effects in the cardiovascular system where they work additively to relax blood 
vessels (Lidbury, Antunes, de Nucci, & Vane, 1989) and synergistically to inhibit platelet aggregation 
(Kirkby, et al., 2013; Levin, Weksler, & Jaffe, 1982; Lidbury, et al., 1989; P. S. Macdonald, Read, & 




The idea that COX-2 in endothelial cells produces PGI2 and that inhibition of COX-2 in these cells 
accounts for the cardiovascular side effects caused by NSAIDs is frequently advanced, although the 
relative contribution of systemic versus regional vascular COX-2 to protecting the cardiovascular 
system remains the subject of debate (Funk & FitzGerald, 2007; Mitchell & Kirkby, 2019; Yu, Ricciotti, 
Grosser, & Fitzgerald, 2009). Nevertheless, while in general terms COX-2 (in comparison with COX-1) 
is only sparsely expressed in most areas of endothelium, where its activity has little impact on gross 
levels of PGI2 formation in vitro and in vivo (Kirkby, et al., 2012; Kirkby, et al., 2013; Liu, et al., 2012), 
endothelial COX-2 does protect the cardiovascular system. For example, in genetically modified mice 
where COX-2 is selectively knocked out of endothelial cells, thrombosis (Mitchell, et al., 2019; Yu, et 
al., 2012) and atherosclerosis (Tang, et al., 2014) are increased while deletion of COX-2 from 
endothelial cells and vascular smooth muscle increases blood pressure (Yu, et al., 2012). However, it 
is not yet clear where the cardio-protective endothelial COX-2 is expressed or how PGI2 derived from 
COX-2 and COX-1 operates separately and together to maintain cardiovascular health.  	
 
5.2.3. Gut 
A role for inhibition of COX-2 in the gut as a contributing factor to NSAID-associated cardiovascular 
side effects has yet to be fully explored. However, several pieces of evidence support the hypothesis. 
Firstly, COX-2 is co-expressed with COX-1 in the gut where both isoforms contribute to 
gastrointestinal protection (Wallace, McKnight, Reuter, & Vergnolle, 2000) since traditional NSAIDs 
and (albeit to a less extent) selective COX-2 inhibitors cause increased risk of gastrointestinal events 
(Coxib, et al., 2013). Secondly NSAIDs can increase gut permeability (Bjarnason, Williams, Smethurst, 
Peters, & Levi, 1986; Sigthorsson, et al., 1998) and cause subclinical increases in circulating bacterial 
LPS in rats (Tugendreich, Pearson, Sagartz, Jarnagin, & Kolaja, 2006) and humans (athletes) (Nieman, 
et al., 2006) resulting in ‘metabolic endotoxemia’ (Marlicz, Loniewski, Grimes, & Quigley, 2014). 
Thirdly, metabolic endotoxemia primes the cardiovascular system to inflammation and is associated 
with increased risk of a wide range of cardiovascular diseases (Charalambous, Stephens, Feavers, & 
Montgomery, 2007; Marlicz, et al., 2014; Wiedermann, et al., 1999). However, complicating this idea 
is the fact that selective COX-2 inhibitors, which carry similar risk of cardiovascular side effects to 
traditional NSAIDs, are associated with reduced gastrointestinal side effects (Coxib, et al., 2013) and 




The case for COX-2 in the thymus as a direct and significant contributor to cardiovascular protection 
is relatively nebulous although some lines of evidence do exist. Firstly, COX-2 is expressed selectively 
in medullary epithelial cells of the human thymus where it may influence immature CD4+ and 
CD8+ thymocytes (Rocca, et al., 2002). Secondly, immune cell regulation by the thymus is important 
in atherosclerosis (Dai, Zhang, Wang, Wu, & Liang, 2018; Tse, Tse, Sidney, Sette, & Ley, 2013). Thirdly, 
COX-2 knockout mice have increased atherosclerosis associated with accumulation of T-lymphocytes 
in atherosclerotic plaques (Kirkby, et al., 2014). Finally, a link between immunomodulation towards 
a Th1 response and plaque instability as a mechanism to explain cardiovascular side effects caused 
by COX-2 inhibitors has been suggested (Padol & Hunt, 2010). 
 
5.2.5. Brain 
COX-2 is constitutively expressed throughout the central nervous system where its activity 
contributes to fundamental brain functions including synaptic activity, memory and functional 
hyperaemia. NSAIDs cross the blood brain barrier (Dembo, Park, & Kharasch, 2005; Parepally, 
Mandula, & Smith, 2006) and much has been made of the inflammatory effects of COX-2 in the brain 
with a large body of unresolved literature that implicates a therapeutic role for NSAIDs in 
degenerative conditions such as Alzheimer Disease (Guan & Wang, 2019; Trepanier & Milgram, 
2010). However, despite the importance of the central nervous system in regulating blood pressure 
(Wyss & Carlson, 1999) and cardiovascular homeostasis (Tahsili-Fahadan & Geocadin, 2017) a firm 
link with NSAIDs acting on central COX-2 to cause cardiovascular side effects has not been made. 
Nevertheless, oral administration of indomethacin in healthy volunteers reduces cerebral blood flow, 
which may be therapeutically useful in the treatment of traumatic brain injury (Slavik & Rhoney, 
1999). In addition, early studies in rats showed that intracerebroventricular administration of the 
most abundant prostanoid in the brain, PGD2, did not affect blood pressure (Siren, 1982a). Others 
showed that arachidonic acid, PGF2α (Siren, 1982b) or PGE2 increased blood pressure while PGI2 
reduced blood pressure and the NSAID indomethacin had no effect  (Kondo, Okuno, Saruta, & Kato, 
1979). In separate studies, intracerebroventricular administration of the NSAIDs ketorolac or 
meclofenamate blocked the excitatory cardiovascular and renal sympathetic responses to circulating 
TNFα (Z. H. Zhang, Wei, Francis, & Felder, 2003) and the pressor effects of angiotensin II (Inoue, 
Crofton, & Share, 1990), respectively. Conditional neuronal COX-2 knockout mice have been made 
(Vardeh, et al., 2009), but have not as yet been used in cardiovascular models.  
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Tissue 
Example hypothesis attributed to ‘tissue hot spot’ COX-2 expression and 
cardiovascular health/disease 
Kidney 
“COX-2 in the kidney protects the cardiovascular by restraining blood pressure and 
limiting circulating levels of hypertensive mediates such as ADMA” 
Endothelium 
“Endothelial COX-2 drives production of the protective, anti-thrombotic hormone 
prostacyclin and its inhibition to increased thrombosis” 
Gut 
“COX-2 inhibition increases gut permeability leading to metabolic endotoxemia 
(subclinical, chromic increased plasma bacteria/LPS) and increased cardiovascular 
risk due to vascular inflammation” 
Thymus 
“COX-2 inhibition in the thymus disrupts the balance of T cells accelerating 
atherosclerosis’  
Brain 
“COX-2 inhibition in the brain disrupts central control of cardiovascular 
homeostasis leading to increased blood pressure” 
Table 1. Hypotheses for how distant COX-2 in particular organ systems could provide systemic 
cardiovascular protection. 
 
6. Summary and future directions 
COX and the PGI2:TXA2 balance is fundamental to cardiovascular health and disease. Drugs that work 
by manipulating this balance towards cardiovascular protection such as aspirin, PGI2, PGE1 and EPA 
protect millions from cardiovascular disease around the world, although the full potential of 
harnessing this protective pathway has yet to be realized. As we learn more, using tools such as cell 
specific knockout and transgenic mouse models in conjunction with increased availability of human 
omic data relevant for personalized medicine, new cardio-protective drugs based on this pathway 
will be developed. Just as important to understand and mitigate are the cardiovascular side effects 
caused by inhibiting COX-2 with NSAIDs. NSAIDs are critically important pain medications, with 
aspirin and ibuprofen, listed in the World Health Organization list of essential medicines. Some drugs 
in this class can also reduce cancer risk but are not used because of concerns about side effects. To 
develop improved therapeutics we need to understand the mechanisms by which COX-2 protects the 
cardiovascular system and so identify biomarkers of those most at risk. With this knowledge we can 
design new drug combinations/formulations that retain efficacy against pain and inflammation with 





Figure 2. Potential mechanisms of COX-1- and COX-2-mediated cardiovascular protection arising 
from local expression in discrete organ systems. 
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